Skip to main content

Clinical trial 1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administeredonce a day in patients with advanced malignancies, with repeated administration in patients with
clinical benefit

Cancers
Organ solid tumors
Trial status Trial open for recruitment
Investigator
Trial type
Prospective interventional
Phase Trial phase 1
Academic trial Non
Sponsor Boehringer Ingelheim
EudraCT Identifier 2015-001111-12
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02516553
Inclusion criteria any line RECIST 1.1
Last update